The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups.

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

GlaxoSmithKline is set to launch its COPD triple therapy in the US - and must now show that it can maximise sales of the drug with blockbuster potential. Approved yesterday by the FDA, Trelegy ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript February 26, 2025 Theravance Biopharma, Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, expectations ...

Notably, NTLA-2001, the company’s lead in vivo therapy for ATTR amyloidosis ... the CF franchise, Trelegy, Tremfya, and new royalty acquisitions.” In 2024, the company increased its ...

It launched Trelegy Ellipta, the countrys first single inhaler triple therapy (SITT) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) patients. It launched Augmentin ...

Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% coinsurance. Trelegy Ellipta ...